---
title: "诺和诺德股价盘后升一成  减肥口服药获 FDA 批准"
description: "诺和诺德的减肥口服药获得美国 FDA 批准，将与礼来竞争减肥药市场。该药含有 25 毫克司美格鲁肽，与 Wegovy 和 Ozempic 注射剂成分相同，并以 Wegovy 品牌销售。消息公布后，诺和诺德股价盘后上涨 10.56% 至 53.18 美元。研究显示，服用该药的人平均减重 16.6%，而安慰剂组为 2.7%。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/270550940.md"
published_at: "2025-12-23T00:48:18.000Z"
---

# 诺和诺德股价盘后升一成  减肥口服药获 FDA 批准

> 诺和诺德的减肥口服药获得美国 FDA 批准，将与礼来竞争减肥药市场。该药含有 25 毫克司美格鲁肽，与 Wegovy 和 Ozempic 注射剂成分相同，并以 Wegovy 品牌销售。消息公布后，诺和诺德股价盘后上涨 10.56% 至 53.18 美元。研究显示，服用该药的人平均减重 16.6%，而安慰剂组为 2.7%。

美国食品药物管理局 (FDA) 批准诺和诺德 (NVO.US) 一款减肥口服药，这将与竞争对手礼来 (LLY.US) 争夺减肥药市场。

该款减肥药含有 25 毫克司美格鲁肽，与注射剂 Wegovy 及 Ozempic 的活性成分相同，并将以 Wegovy 的品牌名销售。在获批消息公布后，诺和诺德股价在盘后上升 10.56% 至 53.18 美元。

根据一项为期 64 周的后期研究表明，每天服用 25 毫克口服索马鲁肽的人士平均减重 16.6%，而服用安慰剂的参与者平均减重 2.7%。

### Related Stocks

- [NVO.US - 诺和诺德公司](https://longbridge.com/zh-CN/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Biocon aims for revenue surge with rollout of generic weight-loss drugs | Biocon aims for high double-digit revenue growth with the global launch of generic weight-loss drugs, including versions | [Link](https://longbridge.com/zh-CN/news/275900960.md) |
| Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) | Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00 | [Link](https://longbridge.com/zh-CN/news/275719942.md) |
| Novo Nordisk CFO Karsten Munk Knudsen Sells Shares Worth Over DKK 8.3 Million | Novo Nordisk A/S announced that CFO Karsten Munk Knudsen sold 26,246 shares for DKK 8.3 million at DKK 315.60 each and 3 | [Link](https://longbridge.com/zh-CN/news/275652909.md) |
| Savvy Advisors Inc. Purchases 22,138 Shares of Novo Nordisk A/S $NVO | Savvy Advisors Inc. increased its stake in Novo Nordisk A/S by 83.0% in Q3, acquiring 22,138 shares, bringing its total  | [Link](https://longbridge.com/zh-CN/news/275761183.md) |
| Oppenheimer Asset Management Inc. Has $31.35 Million Stock Position in Novo Nordisk A/S $NVO | Oppenheimer Asset Management Inc. increased its stake in Novo Nordisk A/S by 14.4% in Q3, holding 565,007 shares valued  | [Link](https://longbridge.com/zh-CN/news/275287765.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。